2020 IL 125020
Ill.2020Background
- Essure, a permanent contraceptive developed by Conceptus (CA), was acquired and marketed by Bayer (incorporated outside Illinois), which continued FDA post‑market duties.
- Two consolidated Illinois actions (Rios and Hamby) included Illinois resident lead plaintiffs plus ~150 nonresident plaintiffs alleging Essure caused serious injuries implanted and treated outside Illinois.
- Nonresidents alleged Bayer conducted clinical trials, physician training (Essure Accreditation Program), and marketing/regulatory work in Illinois and thus Illinois courts have specific personal jurisdiction over Bayer for all plaintiffs’ claims.
- Trial courts and the Illinois appellate court denied Bayer’s motions to dismiss nonresidents’ claims for lack of personal jurisdiction, relying on in‑state testing/marketing to connect the claims to Illinois (citing M.M.).
- Illinois Supreme Court granted review, consolidated the appeals, and considered whether federal due process permits Illinois to exercise specific jurisdiction over out‑of‑state plaintiffs’ out‑of‑state injuries when the challenged conduct did not occur in Illinois.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Illinois may exercise specific personal jurisdiction over Bayer for nonresident plaintiffs injured outside Illinois | Plaintiffs: Bayer’s in‑state clinical trials, training program, marketing, and regulatory work tie the nonresidents’ claims to Illinois | Bayer: Nonresidents’ injuries, implants, and physicians are outside Illinois; no causal nexus between Illinois activities and those claims | Held: No. Specific jurisdiction requires a connection between the forum and the nonresidents’ claims; that nexus is absent here (Bristol‑Myers controlling). |
| Whether allegations of in‑state clinical trials and marketing suffice post‑Bristol‑Myers to establish relatedness | Plaintiffs: Those in‑state activities are part of a nationwide course of conduct that produced the same injuries | Bayer: General in‑state activities cannot establish specific jurisdiction over unrelated out‑of‑state claims | Held: Bristol‑Myers forecloses using general in‑state activity to assert specific jurisdiction over nonresident claims that do not arise from those activities. |
| Whether exercising jurisdiction would be reasonable under fairness/interest factors | Plaintiffs: Illinois has interest and judicial economy favors adjudicating all claims together | Bayer: Illinois has little interest in adjudicating claims that did not arise there; burden and inefficiency weigh against jurisdiction | Held: Unreasonable to exercise jurisdiction—forum interest and plaintiffs’ convenience do not overcome lack of relatedness. |
| Whether prior Illinois precedent (M.M.) remains good law | Plaintiffs: M.M. supports jurisdiction based on in‑state testing/clinical ties | Bayer: M.M. conflicts with Bristol‑Myers and must yield | Held: M.M. is inconsistent with Bristol‑Myers and no longer viable law in Illinois. |
Key Cases Cited
- Bristol‑Myers Squibb Co. v. Superior Court of California, 137 S. Ct. 1773 (2017) (specific jurisdiction requires a connection between the forum and each nonresident plaintiff’s claim)
- World‑Wide Volkswagen Corp. v. Woodson, 444 U.S. 286 (1980) (Due Process requires minimum contacts for personal jurisdiction)
- Daimler AG v. Bauman, 571 U.S. 117 (2014) (general jurisdiction exists only where corporation is "at home")
- Goodyear Dunlop Tires Operations v. Brown, 564 U.S. 915 (2011) (limits on general jurisdiction based on continuous and systematic contacts)
- Burger King Corp. v. Rudzewicz, 471 U.S. 462 (1985) (specific jurisdiction requires purposeful availment and that claims arise from forum‑directed activities)
- Walden v. Fiore, 571 U.S. 277 (2014) (jurisdictional analysis focuses on relationship among defendant, forum, and litigation)
- BNSF Ry. Co. v. Tyrrell, 137 S. Ct. 1549 (2017) (distinguishes general and specific jurisdiction; clarifies limits on state courts’ reach)